跳至主要内容
临床试验/NCT00718705
NCT00718705已完成3 期

Reduction of Spontaneous Prematurity: Impact of Antibiotic Treatment (Josamycin) in Case of Positive PCR for Ureaplasma Spp and/or Mycoplasma Hominis in Amniotic Fluid

Assistance Publique - Hôpitaux de Paris1 个研究点 分布在 1 个国家目标入组 3,200 人开始时间: 2008年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
3,200
试验地点
1
主要终点
Premature birth

研究概览

简要总结

The purpose of this study is to test the effectiveness of an antibiotic treatment (Josamycin) in the case of positive PCR for Ureaplasma spp. and/or Mycoplasma hominis in the second quarter on the risk of premature birth.

详细描述

Infection would be the cause of 40 % of spontaneous premature deliveries. The physiopathological hypothesis accepted is a premature ascent of present bacteria in the low genital ways towards the decidual, the foetal membranes then the amniotic liquid. These bacteria are responsible for an inflammatory reaction to the interface feto-maternal characterized by the production of proinflammatory cytokines and pro-contractants agents (prostaglandins, oxytocin) by the decidual and the membranes.

These mediators cause uterine contractions, a maturation of the uterine collar, a rupture of the membranes then a premature birth.

Several recent publications show on the one hand that Mycoplasma hominis and Ureaplasma spp. are the bacteria most frequently found in the amniotic liquid in the second quarter of the pregnancy and that a positive PCR for these bacteria is associated with a premature birth.

A probable assumption would be that Mycoplasma hominis or Ureaplasma spp. cause a premature birth by infecting the fetal membranes and the decidual, then activating the immune system and the pro-inflammatory production of cytokines. These bacteria are sensitive to antibiotic treatment.

Nevertheless, no randomized controlled trials have been carried out to determine wether an antibiotic treatment would decrease spontaneous prematurity in the case of positive PCR in the amniotic liquid.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Patient older ≥ 18 years
  • French speaking
  • Women who have an amniocentesis between 15 and 20 weeks of amenorrhoea for an antenatal diagnosis
  • Affiliated to social security or an equivalent system
  • Karyotype analysis and ultrasound morphological normal (apart from minor signs of trisomy 21)
  • Clear amniotic fluid (not contaminated by the mother's blood)
  • Gestational age is between 15 WA(day+0) and 20 WA(day+6)
  • Patient have not allergy to macrolides
  • Do not have cure underway by macrolide
  • Patient followed during her pregnancy in an investigator site
  • Informed consent and signed

排除标准

  • No speaking french
  • Having an allergy to macrolides
  • Having a multiple pregnancy
  • Morphological Anomaly
  • Patient no consented
  • Lactose Intolerance
  • Not agreed to participate

研究组 & 干预措施

1

Experimental

josamycin

干预措施: Josamycin (Drug)

2

Placebo Comparator

Placebo

干预措施: Placebo (Drug)

结局指标

主要结局

Premature birth

时间窗: between 22 and 37 completed weeks of pregnancy.

次要结局

  • Antenatal :occurence of a miscarriage late(between 16 and 22 weeks of amenorrhoea)
  • Antenatal : premature delivery(at week of amenorrhea <= 34, 32, 28)
  • Antenatal : hospitalisation for risk of premature delivery(antenatal period)
  • antenatal : Number of day of hospitalisation for risk of premature delivery(antenatal period)
  • Antenatal : premature rupture of membranes(before 37 week of amenorrhea)
  • Antenatal : occurence of chorioamnionitis defined by 2 of the following criteria :maternal temperature > 38°C, uterine contractions, Fetid leucorrhoeas, foetal tachycardia > 160bpm, C reactive protein >10mg/l(antenatal period)
  • During childbirth : Hyperthermia > 38°C(Childbirth period)
  • During childbirth : fetal tachycardia > 160 bpm(childbirth period)
  • Post-partum : Hyperthermia > 38°C for more than 24hours(post partum period)
  • Post partum :need an antibiotic treatment for more than 48 hours(post partum period)
  • Neonatal : neonatal mortality late(from day 7 to day 28)
  • Neonatal : early neonatal mortality(from day 0 to day 6)
  • Neonatal morbidity : immediate neonatal state(neonatal period)
  • Neonatal morbidity : infection(neonatal period)
  • Neonatal morbidity : respiratory disease(neonatal period)
  • Neonatal morbidity : digestive disease(neonatal period)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验